Circulating Blood-Brain Barrier Proteins for Differentiating Ischaemic Stroke Patients from Stroke Mimics
Open Access
- 22 October 2024
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 14 (11) , 1344
Abstract
Background: Stroke is one of the leading causes of death and disability worldwide. The diagnosis of stroke remains largely clinical, yet widely used stroke scoring systems and brain imaging do not satisfactorily allow the distinction of ischaemic stroke (IS) patients from stroke mimics (SMs). Blood biomarkers are promising tools that could facilitate clinical triage. Methods: This study recruited 66 patients with IS and 24 SMs. The levels of Glial fibrillary acidic protein (GFAP), Neuron-specific enolase (NSE), Neurofilament light chain (NfL) and blood-brain barrier (BBB) proteins [Occludin (OCLN), Zonula occludens 1 (ZO-1), Claudin-5] in blood serum were measured by enzyme-linked immunosorbent assay technique. Biomarker levels in IS patients and SMs were compared using the Mann–Whitney U test. Multivariable logistic regression analysis was used to evaluate the diagnostic performance of biomarkers in combination with the National Institutes of Health Stroke Scale (NIHSS) score. Results: More significant differences in circulating GFAP, NfL, OCLN, ZO-1, and Claudin-5 but not NSE were found in IS patients compared to SMs. A combination of circulating ZO-1, Claudin-5, and OCLN with NIHSS score gives the highest diagnostic accuracy, sensitivity, and specificity. Conclusions: A prediction model with circulating BBB proteins in combination with NIHSS score differentiates between IS patients and SMs.Keywords
All Related Versions
Funding Information
- Medical Research Council, UK Developmental Pathway Gap Fund (MR/Y503460/1)
- King Saud University, Saudi Arabia (MR/Y503460/1)
This publication has 47 references indexed in Scilit:
- Tight junction proteins related to blood-brain barrier and their regulatory signaling pathways in ischemic strokeBiomedicine & Pharmacotherapy, 2023
- Diagnostic Accuracy of Glial Fibrillary Acidic Protein and Ubiquitin Carboxy-Terminal Hydrolase-L1 Serum Concentrations for Differentiating Acute Intracerebral Hemorrhage from Ischemic StrokeNeurocritical Care, 2020
- Blood Biomarkers for Stroke Diagnosis and ManagementNeuroMolecular Medicine, 2019
- Glial fibrillary acidic protein (GFAP) plasma levels distinguish intracerebral hemorrhage from cerebral ischemia in the early phase of acute strokeJournal of the Neurological Sciences, 2015
- The use of serum glial fibrillary acidic protein test as a promising tool for intracerebral hemorrhage diagnosis in Chinese patients and prediction of the short-term functional outcomesNeurological Sciences, 2015
- Prognostic value of neuron specific enolase and IL-10 in ischemic stroke and its correlation with degree of neurological deficitClinica Chimica Acta, 2013
- Correlation of Brain Biomarker Neuron Specific Enolase (NSE) with Degree of Disability and Neurological Worsening in Cerebrovascular StrokeIndian Journal of Clinical Biochemistry, 2011
- Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic strokeClinical Neurology and Neurosurgery, 2006
- Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic strokeJournal of the Neurological Sciences, 2004
- Role and importance of biochemical markers in clinical cardiologyEuropean Heart Journal, 2004